ArticleJournal of the Pediatric Infectious Diseases Society2015
Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children.
Article in Journal of the Pediatric Infectious Diseases Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Enterovirus D68 receptor usage: from static attachment to dynamic entry.Journal of virology · 2026Review
- Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation.The Journal of infectious diseases · 2026Article
- Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.Heliyon · 2022Review
- Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence.The Journal of clinical investigation · 2021Article
- Parainfluenza virus entry at the onset of infection.Advances in virus research · 2021Article
- Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020Review
- Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy.Annals of hematology · 2020Article
- Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs.Clinical microbiology reviews · 2019Review
- Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.Infectious disease clinics of North America · 2019Review
- Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.Antiviral research · 2018Article
- Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.Frontiers in microbiology · 2018Review
- Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.Frontiers in microbiology · 2018Review
- Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management.Drugs & aging · 2017Review
- Characterizing the Cellular Immune Response to Parainfluenza Virus 3.The Journal of infectious diseases · 2017Article
- Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?The Journal of infectious diseases · 2017Article
- Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies.Clinics in chest medicine · 2017Review
- Antiviral therapy for respiratory viral infections in immunocompromised patients.Expert review of anti-infective therapy · 2017Review
- Antiviral Treatments.Clinics in chest medicine · 2017Review
- Assessment of the Usefulness of Multiplex Real-Time PCR Tests in the Diagnostic and Therapeutic Process of Pneumonia in Hospitalized Children: A Single-Center Experience.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundParainfluenza virus (PIV), a common pediatric pathogen, is associated with significant morbidity in immunocompromised (IC) hosts. DAS181, a novel sialidase fusion protein inhibitor, seems to be effective against PIV in vitro and in vivo; its use in IC children has not been evaluated.
methodsPatients were diagnosed with PIV infection using a quantitative reverse transcription-polymerase chain reaction. DAS181 was obtained under emergency investigational new drug applications and was administered via aerosol chamber or nebulizer. Patients were assessed daily for their clinical condition and adverse outcomes.
resultsFour pediatric hematopoietic cell transplantation (HCT) patients with PIV detected in respiratory specimens were identified and treated with DAS 181. Patients 1 and 2 were diagnosed with PIV lower respiratory tract infection (LRTI) by bronchoalveolar lavage at 9 months and 2 days after allogeneic transplantation, respectively. Patient 3 was on chemotherapy prior to planned autologous HCT at time of PIV diagnosis from a nasal swab. Patient 4 was diagnosed with PIV via nasal wash 2 days after HCT. Patients 1-3 had clinical symptoms and chest imaging consistent with LRTI. Inhaled DAS181 was administered for 5-10 days. All 4 patients tolerated therapy well. Clinical improvement in oxygen requirement and respiratory rate was observed in all patients who required oxygen at therapy initiation. Viral load decreased in all patients within 1 week of therapy and became undetectable by day 3 of therapy in patient 3.
conclusionDAS181 was used to treat 4 severely IC pediatric patients with PIV disease. The drug was well tolerated. Improvement in both viral loads and symptoms after initiation of therapy was observed in all cases. This report supports prospective, randomized studies in IC patients with PIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.